ViiV's Dovato: Treatment-Naive HIV Is Earmarked For The "Complete Regimen"
The first approval in the US of a once-daily single-tablet, two-drug regimen for treatment-naive HIV from the HIV/AIDS therapy specialist, ViiV Healthcare, suggests a shift away from three-drug regimens for HIV/AIDS could be gathering pace.
You may also be interested in...
License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.
Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.
The shingles vaccine Shingrix and new HIV and respiratory drugs drove first quarter growth at GlaxoSmithKline, even as Advair and Breo sales were impacted by a generic.